Annual CFO
-$47.02 M
+$55.87 M+54.30%
31 December 2023
Summary:
Xeris Biopharma Holdings annual cash flow from operations is currently -$47.02 million, with the most recent change of +$55.87 million (+54.30%) on 31 December 2023. During the last 3 years, it has risen by +$33.53 million (+41.63%). XERS annual CFO is now -192.30% below its all-time high of -$16.09 million, reached on 31 December 2016.XERS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$8.30 M
+$2.04 M+19.74%
30 September 2024
Summary:
Xeris Biopharma Holdings quarterly cash flow from operations is currently -$8.30 million, with the most recent change of +$2.04 million (+19.74%) on 30 September 2024. Over the past year, it has increased by +$6.30 million (+43.16%). XERS quarterly CFO is now -211.16% below its all-time high of $7.47 million, reached on 31 December 2023.XERS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$31.48 M
+$6.30 M+16.68%
30 September 2024
Summary:
Xeris Biopharma Holdings TTM cash flow from operations is currently -$31.48 million, with the most recent change of +$6.30 million (+16.68%) on 30 September 2024. Over the past year, it has increased by +$39.13 million (+55.41%). XERS TTM CFO is now -794.71% below its all-time high of -$3.52 million, reached on 31 March 2017.XERS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XERS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +54.3% | +43.2% | +55.4% |
| 3 y3 years | +41.6% | +63.3% | +59.4% |
| 5 y5 years | +16.4% | +72.8% | +66.2% |
XERS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +54.3% | -211.2% | +82.8% | at high | +73.9% |
| 5 y | 5 years | at high | +54.9% | -211.2% | +82.8% | at high | +73.9% |
| alltime | all time | -192.3% | +54.9% | -211.2% | +82.8% | -794.7% | +73.9% |
Xeris Biopharma Holdings Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.30 M(-19.7%) | -$31.48 M(-16.7%) |
| June 2024 | - | -$10.35 M(-49.0%) | -$37.79 M(-8.2%) |
| Mar 2024 | - | -$20.30 M(-371.8%) | -$41.19 M(-12.4%) |
| Dec 2023 | -$47.02 M(-54.3%) | $7.47 M(-151.1%) | -$47.02 M(-33.4%) |
| Sept 2023 | - | -$14.61 M(+6.3%) | -$70.61 M(-4.3%) |
| June 2023 | - | -$13.74 M(-47.4%) | -$73.76 M(-8.5%) |
| Mar 2023 | - | -$26.14 M(+62.2%) | -$80.62 M(-21.6%) |
| Dec 2022 | -$102.89 M(+7.7%) | -$16.12 M(-9.2%) | -$102.89 M(-11.1%) |
| Sept 2022 | - | -$17.75 M(-13.9%) | -$115.72 M(-4.0%) |
| June 2022 | - | -$20.61 M(-57.4%) | -$120.58 M(+0.5%) |
| Mar 2022 | - | -$48.41 M(+67.2%) | -$119.99 M(+25.6%) |
| Dec 2021 | -$95.53 M(+18.6%) | -$28.95 M(+28.0%) | -$95.53 M(+23.3%) |
| Sept 2021 | - | -$22.61 M(+12.9%) | -$77.46 M(+7.8%) |
| June 2021 | - | -$20.02 M(-16.4%) | -$71.83 M(-4.9%) |
| Mar 2021 | - | -$23.96 M(+120.4%) | -$75.57 M(-6.2%) |
| Dec 2020 | -$80.56 M | -$10.87 M(-36.0%) | -$80.56 M(-18.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$16.98 M(-28.5%) | -$99.26 M(-12.0%) |
| June 2020 | - | -$23.76 M(-17.9%) | -$112.86 M(+0.6%) |
| Mar 2020 | - | -$28.95 M(-2.1%) | -$112.14 M(+7.5%) |
| Dec 2019 | -$104.35 M(+85.4%) | -$29.57 M(-3.3%) | -$104.35 M(+12.1%) |
| Sept 2019 | - | -$30.58 M(+32.8%) | -$93.11 M(+18.7%) |
| June 2019 | - | -$23.04 M(+8.9%) | -$78.44 M(+12.7%) |
| Mar 2019 | - | -$21.15 M(+15.4%) | -$69.63 M(+23.7%) |
| Dec 2018 | -$56.28 M(+128.2%) | -$18.34 M(+15.2%) | -$56.28 M(+19.6%) |
| Sept 2018 | - | -$15.92 M(+11.9%) | -$47.04 M(+28.2%) |
| June 2018 | - | -$14.22 M(+82.2%) | -$36.70 M(+26.8%) |
| Mar 2018 | - | -$7.80 M(-14.2%) | -$28.95 M(+17.4%) |
| Dec 2017 | -$24.66 M(+53.3%) | -$9.10 M(+63.2%) | -$24.66 M(+58.5%) |
| Sept 2017 | - | -$5.58 M(-13.8%) | -$15.56 M(+55.8%) |
| June 2017 | - | -$6.47 M(+83.8%) | -$9.99 M(+183.8%) |
| Mar 2017 | - | -$3.52 M | -$3.52 M |
| Dec 2016 | -$16.09 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual cash flow from operations?
- What is the all time high annual CFO for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual CFO year-on-year change?
- What is Xeris Biopharma Holdings quarterly cash flow from operations?
- What is the all time high quarterly CFO for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly CFO year-on-year change?
- What is Xeris Biopharma Holdings TTM cash flow from operations?
- What is the all time high TTM CFO for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM CFO year-on-year change?
What is Xeris Biopharma Holdings annual cash flow from operations?
The current annual CFO of XERS is -$47.02 M
What is the all time high annual CFO for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual cash flow from operations is -$16.09 M
What is Xeris Biopharma Holdings annual CFO year-on-year change?
Over the past year, XERS annual cash flow from operations has changed by +$55.87 M (+54.30%)
What is Xeris Biopharma Holdings quarterly cash flow from operations?
The current quarterly CFO of XERS is -$8.30 M
What is the all time high quarterly CFO for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly cash flow from operations is $7.47 M
What is Xeris Biopharma Holdings quarterly CFO year-on-year change?
Over the past year, XERS quarterly cash flow from operations has changed by +$6.30 M (+43.16%)
What is Xeris Biopharma Holdings TTM cash flow from operations?
The current TTM CFO of XERS is -$31.48 M
What is the all time high TTM CFO for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM cash flow from operations is -$3.52 M
What is Xeris Biopharma Holdings TTM CFO year-on-year change?
Over the past year, XERS TTM cash flow from operations has changed by +$39.13 M (+55.41%)